Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.71 |
| ▸ | MMP1 | P03956 | 5/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508320 | 0.92 | MME (0.59) | MMEEPHX2KDM1A | |
| SCHEMBL7441951 | 0.83 | MME (1.00) | MMEMMP1MAOA | |
| SCHEMBL7441955 | 0.83 | MME (1.00) | MMEMMP1MAOA | |
| SCHEMBL7441960 | 0.81 | MME (0.69) | MMEMMP1MAOAEPHX2DRD2 | |
| SCHEMBL7441944 | 0.81 | MME (0.69) | MMEMMP1MAOAEPHX2DRD2 | |
| SCHEMBL7449785 | 0.78 | MME (0.79) | MMEMAOAEPHX2DRD2OPRM1 | |
| SCHEMBL7446720 | 0.76 | MME (0.71) | MMEEPHX2KDM1A | |
| SCHEMBL7446715 | 0.76 | MME (0.71) | MMEEPHX2KDM1A | |
| SCHEMBL7448573 | 0.76 | MME (0.70) | MMEKDM1A | |
| SCHEMBL7448568 | 0.76 | MME (0.70) | MMEKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885MMP1 385/4885MAOA 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.